Thursday, July 17, 2025
Welcoming Remarks
Harold Burstein, MD, PhD
50 Years of Radiation Therapy
Abram Recht, MD
Stardard Radiation Therapy: The Long and the Short
Julia Wong, MD
The Future of Breast Radiation Therapy
Atif Khan, MD, MSD
Radiopharmaceuticals
Heather Jacene, MD
Q&A
Abram Recht, MD; Atif Khan, MS, MSD; Julia Wong, MD; Heather Jacene, MD
Lobular Breast Cancer
Stuart Schnitt, MD
ctDNA: The Evolving Role for Molecular Diagnostics
Heather Parsons, MS, MPH
Q&A
Stuart Schnitt, MD; Heather Parsons, MD
Break
What's New In Supportive Care: The Management of Gastrointestinal Side Effects
Lindsay Shaw, AOCNP, ACHPN
Essentials of Germline Genetics
Huma Rana, MD, MPH
Q&A
Huma Rana, MD, MPH; Lindsay Shaw, AOCNP, ACHPN
Schwartz Rounds: A Complex Case
Ann Partridge, MD, MPH
Schwartz Rounds Q&A
Ann Partridge, MD, MPH
Break (pick up lunch)
Tumor Board: Early Breast Cancer
Harold Burstein, MD, PhD; Tari King, MD; Faina Nakhlis, MD; Julia Wong, MD; Brittany Bychkovsky, MD; Laura Spring, MD; Erica Warner, ScD, MPH Filipa Lynce, MD
Break
New Approaches in Early Stage HER2 Positive Breast Cancer
Adrienne G. Waks, MD
The Progress Continues: Late Stage HER2 Positive Breast Cancer
Sarah Sammons, MD
Can We Cure Metastatic Breast Cancer
Nancy Lin, MD
Q&A
Sara Tolaney, MD, MPH; Adrienne G. Waks, MD; Sarah Sammons, MD; Nancy Lin, MD
Break
Racial Differences in Breast Cancer Survival Between Black and White Women According to Tumor Subtype
Erica Warner, ScD, MPH
Inflammatory Breast Cancer
Filipa Lynce, MD
Early Drug Discovery in Breast Cancer
Antonio Giordano, MD, PhD
Q&A
Filipa Lynce, MD; Antonio Giordano, MD, PhD; Erica Warner, ScD, MPH
Reception
Friday, July 18, 2025
Session IV Surgery: Oncoplastic Reconstruction: Common Indications and Outcomes
Indi Sinha, MD
The Axilla After Neoadjuvant Therapy: How Much is Too Much?
Tari King, MD
Implications of the SOUND Trial
Olga Kantor, MD, MS
Cryoblation Instead of Surgery
Francys Verdial, MD
Q&A
Barbara Smith, MD, PhD; Indi Sinha, MD; Tari King, MD; Olga Kantor, MD, MS; Francys Verdial, MD
Immunotherapy in Early Breast Cancer: Today and Tomorrow
Marleen Kok, MD, PhD
Immunotherapy in Early Breast Cancer: Today and Tomorrow
Marleen Kok, MD, PhD
Break
Small TNBCs: How Small Is Small Enough?
Steven Isakoff, MD, PhD
Antibody Drug Conjugates in TNBC and Refractory ER Positive Metastatic Breast Cancer
Ana Garrido-Castro, MD
Immunotherapy in TNBC
Guilherme Nader Marta
Managing Endocrine Side Effects of Immunotherapy
Elad Sharon, MD, PhD
Q&A
Steven Isakoff, MD, PhD; Ana Garrido-Castro, MD; Guilherme Nader Marta; Elad Sharon, MD, MPH
Break (Pick Up Lunch)
Tumor Board: Advanced Breast Cancer
Barbara Smith, MD, PhD; Rachel Freedman, MD, PhD; Erica Mayer, MD, MPH; Sarah Sammons, MD; Laura Spring, MD; Leticia Varella, MD; Guilherme Nader Marta
Break
New Approaches in Early ER Positive Breast Cancer
Erica Mayer, MD, MPH
PI3K Inhibitors in Metastatic Breast Cancer: Choosing the Right Target
Laura Spring, MD
Advanced ER Positive Breast Cancer: A Surfeit of Choices
Seth Wander, MD, PhD
Emerging Antibody Drug Conjugates in ER Positive Breast Cancer
Paolo Tarantino, MD
Q&A
Erica Mayer, MD, MPH; Laura Spring, MD; Seth Wander, MD, PhD; Paolo Tarantino, MD
Break
Debate: CDK4/6: Which One? For Whom?
Beverly Moy, MD; Shana Berwick, MD
Debate Q&A
Beverly Moy, MD; Shana Berwick, MD
ASCO HIghlights
Harold Burstein, MD, PhD
Closing Remarks
Harold Burstein, MD, PhD